Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/34914 http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e |
Resumo: | Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group. |
id |
UFSP_5af5754ca65bc7bf7e2d7525cb559f04 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/34914 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Teixeira, Sergio Henrique [UNIFESP]Doi, Larissa Morimoto [UNIFESP]Silva, Andre Luiz de Freitas [UNIFESP]Silva, Karine Duarte [UNIFESP]Paes, Angela TavaresHiga, Fabiana Shinzato [UNIFESP]Mendonca, MarceloPrata, Joao AntonioParanhos, Augusto [UNIFESP]Universidade Federal de São Paulo (UNIFESP)Hosp Israelita Albert EinsteinHORPUniv Fed Triangulo Mineiro2016-01-24T14:27:16Z2016-01-24T14:27:16Z2012-06-01Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012.1057-0829http://repositorio.unifesp.br/handle/11600/34914http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e10.1097/IJG.0b013e31820d7e4eWOS:000305084100010Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Universidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilHosp Israelita Albert Einstein, São Paulo, BrazilHORP, Sao Jose Do Rio Preto, SP, BrazilUniv Fed Triangulo Mineiro, Uberaba, MG, BrazilUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilWeb of Science342-348engLippincott Williams & WilkinsJournal of Glaucomaneovascular glaucomaglaucoma drainage implantstriamcinolone acetonideSilicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/349142022-09-27 14:37:28.671metadata only accessoai:repositorio.unifesp.br:11600/34914Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:26:54.445903Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
title |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
spellingShingle |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial Teixeira, Sergio Henrique [UNIFESP] neovascular glaucoma glaucoma drainage implants triamcinolone acetonide |
title_short |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
title_full |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
title_fullStr |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
title_full_unstemmed |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
title_sort |
Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial |
author |
Teixeira, Sergio Henrique [UNIFESP] |
author_facet |
Teixeira, Sergio Henrique [UNIFESP] Doi, Larissa Morimoto [UNIFESP] Silva, Andre Luiz de Freitas [UNIFESP] Silva, Karine Duarte [UNIFESP] Paes, Angela Tavares Higa, Fabiana Shinzato [UNIFESP] Mendonca, Marcelo Prata, Joao Antonio Paranhos, Augusto [UNIFESP] |
author_role |
author |
author2 |
Doi, Larissa Morimoto [UNIFESP] Silva, Andre Luiz de Freitas [UNIFESP] Silva, Karine Duarte [UNIFESP] Paes, Angela Tavares Higa, Fabiana Shinzato [UNIFESP] Mendonca, Marcelo Prata, Joao Antonio Paranhos, Augusto [UNIFESP] |
author2_role |
author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Hosp Israelita Albert Einstein HORP Univ Fed Triangulo Mineiro |
dc.contributor.author.fl_str_mv |
Teixeira, Sergio Henrique [UNIFESP] Doi, Larissa Morimoto [UNIFESP] Silva, Andre Luiz de Freitas [UNIFESP] Silva, Karine Duarte [UNIFESP] Paes, Angela Tavares Higa, Fabiana Shinzato [UNIFESP] Mendonca, Marcelo Prata, Joao Antonio Paranhos, Augusto [UNIFESP] |
dc.subject.eng.fl_str_mv |
neovascular glaucoma glaucoma drainage implants triamcinolone acetonide |
topic |
neovascular glaucoma glaucoma drainage implants triamcinolone acetonide |
description |
Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012-06-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:27:16Z |
dc.date.available.fl_str_mv |
2016-01-24T14:27:16Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/34914 http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e |
dc.identifier.issn.none.fl_str_mv |
1057-0829 |
dc.identifier.doi.none.fl_str_mv |
10.1097/IJG.0b013e31820d7e4e |
dc.identifier.wos.none.fl_str_mv |
WOS:000305084100010 |
identifier_str_mv |
Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012. 1057-0829 10.1097/IJG.0b013e31820d7e4e WOS:000305084100010 |
url |
http://repositorio.unifesp.br/handle/11600/34914 http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Journal of Glaucoma |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
342-348 |
dc.publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460292106125312 |